The U.S. Supreme Court today struck down deep Medicare Part B drug reimbursement cuts for many 340B hospitals during 2018 and 2019. The decision does not affect continuation of the cuts in 2020 through this year, however.
UPDATE, June 15, 2022, 12:45 p.m. EDT—The U.S. Centers for Medicare & Medicaid Services said, “We are aware and reviewing the decision.”
The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed
HRSA told Merck today the company's conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop or Merck could face civil monetary penalties.
The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each
A federal district judge today struck down and vacated HRSA's May 2021 finding that AstraZeneca's 340B contract pharmacy policy violates the 340B statute.
A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities use contract pharmacies violates the 340B statute.
If the path to solving the 340B contract pharmacy dispute runs through Congress, "we're prepared to go in that direction,” 340B Health President and CEO Maureen Testoni said today.
For the first time since the 340B contract pharmacy impasse started over a year and a half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of
BMS yesterday imposed restrictions on 340B pricing on most of its covered outpatient drugs, while liberalizing its policy on access to 340B pricing on its expensive cancer drugs Revlimid, Pomalyst, and Thalomid.
Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.
Biopharmaceutical company AbbVie—maker of the expensive and widely prescribed immunosuppressive medication Humira—today became the 11th drug manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.
The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.
The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health
U.S. District Judge Dabney Friedrich last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies.
A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too